Institutional Review Board, Hospital for Special Surgery
April 08, 2020
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Harry G.Greditzer, IV, MD
Russell F. Warren, MD
David M. Dines, MD
Joshua S. Dines, MD
Edward V. Craig, MD, MPH - Emeritus
This study will include 83 patients who underwent shoulder arthroplasty with hybrid glenoid component versus traditional pegged implant and were included in the prior short-term outcomes study published in 2015.
Patients that are candidates for this study must satisfy the following criteria:
Exclusion criteria include: